Experimental study of gene therapy for malignant glial cells by transfection with IL-12 gene -using SCID mouse model imitating human being-

IL-12基因转染恶性胶质细胞基因治疗的实验研究-利用SCID仿人小鼠模型-

基本信息

  • 批准号:
    08671609
  • 负责人:
  • 金额:
    $ 0.26万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1996
  • 资助国家:
    日本
  • 起止时间:
    1996 至 1997
  • 项目状态:
    已结题

项目摘要

1.Making an Experimental model imitating human beingAfter the intraperitoneal administration of SCID mouse with human mononuclear cells, these human mononuclear cells were detected until 3 weeks. Administration of human IL-2 simultaneously prolonged the life span of human mononuclear cells about 1 or 2 weeks. It suggests that human IL-2 activated human NK cells and T cells. We don't know why some SCID mouse died after the administration early. So it is necessary for experimental model to use the other cytokines.2.IL-12 expression in patients with malignant glioma, having beta-IFN therapyFor patients with malignant astrocytoma or glioblastoma, we underwent immunotherapy with beta-IFN (3 million unit) every other day. During the therapy, NK activity, LAK activity and IL-12 expression were measured. However we cannot find NK activity, LAK activity and IL-12 expresion significantly.3.Transfection of IL-12 gene (p35, p40) into malignant glioma cell lineIL-12 gene could not be successfully introdued into malignant glioma cell line. Both subunits of p35 and p40 are nessesary for active type of IL-12. So we did double transfection of P35 and p40 with electroporation. Now we investigate to find the surest way of induction of IL-12. On the other hand, in vitro study IL-12 induced a considerable antitumor effect from human mononuclear cells on human glioma cell line, even compared with IL-2. However, for the purpose of clinical trial of IL-12, it is important to establish the ex vivo model.
1.模拟人的实验模型的建立将人单个核细胞腹腔注射到SCID小鼠体内后,检测这些人单个核细胞,直至3周。同时给予人IL-2可延长人单核细胞的寿命约1或2周。提示人IL-2可激活人NK细胞和T细胞。我们不知道为什么一些SCID小鼠在给药后过早死亡。2.恶性胶质瘤患者IL-12的表达,β-IFN治疗恶性星形细胞瘤或胶质母细胞瘤患者,采用β-IFN(300万单位)隔日免疫治疗。治疗期间检测NK细胞活性、LAK细胞活性及IL-12表达。IL-12基因(p35、p40)转染恶性胶质瘤细胞系IL-12基因未能成功导入恶性胶质瘤细胞系。p35和p40亚基是IL-12活化所必需的。因此,我们采用电穿孔法进行了P35和p40的双重转染。现在我们研究寻找诱导IL-12的最可靠的方法。另一方面,体外研究表明,即使与IL-2相比,IL-12也能诱导人单核细胞对人脑胶质瘤细胞系产生相当大的抗肿瘤作用。然而,为了进行IL-12的临床试验,建立离体模型是重要的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HASHIMOTO Masaaki其他文献

HASHIMOTO Masaaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HASHIMOTO Masaaki', 18)}}的其他基金

Measurement of endogenous anti-oxidants by non-restraint continuous measuring device: evaluation of its possibility as the hibernation marker.
非约束连续测量装置测量内源性抗氧化剂:评估其作为冬眠标记的可能性。
  • 批准号:
    18390068
  • 财政年份:
    2006
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
A Study on Practical Modeling of Requirement Analysis and Project Management for Unexpected Obstacle Specification of Embedded Software
嵌入式软件意外障碍规范需求分析与项目管理实用建模研究
  • 批准号:
    18500025
  • 财政年份:
    2006
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An investigation of anti-oxidation mechanism in hibernator major organs by means of temperature-independent measurement of the substances related to energy metabolism
通过与温度无关的能量代谢相关物质测量研究冬眠主要器官的抗氧化机制
  • 批准号:
    16390057
  • 财政年份:
    2004
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
A Study on Integration and Improvement of CASE Tools for Practical System Analysis and IT engineer Education
实用系统分析和IT工程师教育CASE工具的集成与改进研究
  • 批准号:
    15500024
  • 财政年份:
    2003
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of hibernation marker and energy metabolism relating substances in the brain and brown fat.
大脑和棕色脂肪中冬眠标志物和能量代谢相关物质的研究。
  • 批准号:
    14370018
  • 财政年份:
    2002
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
A Study on Multiple View Software Modeling for advanced
高级多视图软件建模研究
  • 批准号:
    11680364
  • 财政年份:
    1999
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Research on Domain-Specific Requirement Specifications Description Language and Its Implementation Method in an Example of Architectural Design and Construction
以建筑设计与施工为例的领域特定需求规格描述语言及其实现方法研究
  • 批准号:
    08680373
  • 财政年份:
    1996
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

GLIOMATCH: The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics
GLIOMATCH:恶性胶质瘤免疫肿瘤学媒人:利用空间分辨的放射多组学实现数据驱动的精准医学
  • 批准号:
    10113516
  • 财政年份:
    2024
  • 资助金额:
    $ 0.26万
  • 项目类别:
    EU-Funded
Self-Assembling Camptothecin Nanofiber Hydrogels as Adjunct Therapy for Intraoperative Treatment of Malignant Glioma
自组装喜树碱纳米纤维水凝胶作为恶性胶质瘤术中治疗的辅助疗法
  • 批准号:
    10738545
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
Retrospective prognostic analysis based on molecular information of malignant glioma and malignant meningioma treated with BNCT
基于BNCT治疗恶性胶质瘤和恶性脑膜瘤分子信息的回顾性预后分析
  • 批准号:
    23K19519
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Elucidating the Role of the Gut and Tumor Microbiome in Malignant Glioma
阐明肠道和肿瘤微生物组在恶性胶质瘤中的作用
  • 批准号:
    10573534
  • 财政年份:
    2023
  • 资助金额:
    $ 0.26万
  • 项目类别:
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
抑制野生型 IDH1 作为治疗恶性神经胶质瘤的铁死亡诱导治疗方法。
  • 批准号:
    10539153
  • 财政年份:
    2022
  • 资助金额:
    $ 0.26万
  • 项目类别:
Decoding hyperexcitability in malignant glioma
解码恶性神经胶质瘤的过度兴奋
  • 批准号:
    10529810
  • 财政年份:
    2022
  • 资助金额:
    $ 0.26万
  • 项目类别:
Decoding hyperexcitability in malignant glioma
解码恶性神经胶质瘤的过度兴奋
  • 批准号:
    10666662
  • 财政年份:
    2022
  • 资助金额:
    $ 0.26万
  • 项目类别:
The establishment of drug-delivery system and the 3D-microimaging of intra-cerebral pharmacokinetics in malignant glioma
恶性胶质瘤给药系统的建立及脑内药动学的3D显微成像
  • 批准号:
    21K15554
  • 财政年份:
    2021
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Targeting PARG in malignant glioma therapy
恶性胶质瘤治疗中的靶向 PARG
  • 批准号:
    21K16630
  • 财政年份:
    2021
  • 资助金额:
    $ 0.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IGSF3 promotes tumor progression through synaptic remodeling and hyperexcitability in malignant glioma
IGSF3通过恶性神经胶质瘤的突触重塑和过度兴奋促进肿瘤进展
  • 批准号:
    10315147
  • 财政年份:
    2021
  • 资助金额:
    $ 0.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了